FDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo FDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo
The topical formulation of the JAK1/JAK2 inhibitor was previously approved for atopic dermatitis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 19, 2022 Category: Dermatology Tags: Dermatology News Alert Source Type: news
Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo
Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo
Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation
Fifty-two week... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2022 Category: Drugs & Pharmacology Source Type: news
Topical Ruxolitinib Effective for Vitiligo in Adolescents Topical Ruxolitinib Effective for Vitiligo in Adolescents
Ruxolitinib cream is under review at the US Food and Drug Administration for treating vitiligo in patients ages 12 years and older; the agency is expected to make a decision by July 18.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 8, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
What Is the Difference Between Vitiligo and Piebaldism?
Title: What Is the Difference Between Vitiligo and Piebaldism?Category: Diseases and ConditionsCreated: 7/7/2022 12:00:00 AMLast Editorial Review: 7/7/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - July 7, 2022 Category: Dermatology Source Type: news
Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: a hospital-based case control study in Taiwan - Yang YT, Hsu CH, Wang YF, Chang YJ, Yang HJ, Ko JL, Yang KC.
Vitiligo is an acquired chronic depigmentation disorder that can have a negative impact on the quality of life (QoL). This is especially true for patients with non-white skin. Only few studies have investigated the QoL of Asian patients with vitiligo. We a... (Source: SafetyLit)
Source: SafetyLit - June 13, 2022 Category: International Medicine & Public Health Tags: Age: Young Adults Source Type: news
Namibia: Living With Vitiligo
[New Era] A woman, whose skin colour started changing at the age of 28, says dealing with the condition has been tough but treatment and therapy have helped her accept it. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 19, 2022 Category: African Health Source Type: news
What is in the Differential Diagnosis for Black and White Skin Conditions?
Discussion
This is the third in a short case series of differential diagnoses of colored skin conditions.
An introduction to dermatological terminologies and information about colors can be can be found here.
A differential diagnosis by distribution and common pattern can be found here.
For red, orange and yellow conditions, a review can be found here.
For green, blue and purple conditions, a review can be found here.
For brown and grey conditions, a review can be found here.
Note that any color can be a normal variant for an individual or is physiologic for a given state. When lesions of the opposite color of the normal s...
Source: PediatricEducation.org - May 9, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
JAK Inhibitors Improve Vitiligo, Trials Show JAK Inhibitors Improve Vitiligo, Trials Show
Separate clinical trials of ruxolitinib and ritlecitinib showed both therapies resulted in significant repigmentation in patients with vitiligo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 8, 2022 Category: Consumer Health News Tags: Dermatology News Source Type: news
Significant Improvement in Vitiligo With JAK Inhibitor Therapy
(MedPage Today) -- BOSTON -- About half of patients with longstanding vitiligo obtained significant repigmentation that persisted for at least a year with the topical Janus kinase (JAK) inhibitor ruxolitinib (Opzelura), two randomized trials... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 29, 2022 Category: Dermatology Source Type: news
Black woman, 42, with vitiligo reveals strangers 'fixate on her like she's an animal'
Iomikoe Johnson, 42, from Texas, now adores her 'unique' look, however this wasn't always the case - with the mother feeling suicidal when first being diagnosed with the skin condition, aged 25. (Source: the Mail online | Health)
Source: the Mail online | Health - February 28, 2022 Category: Consumer Health News Source Type: news
Vitiligo From Checkpoint Inhibitors Not Limited to Melanoma Vitiligo From Checkpoint Inhibitors Not Limited to Melanoma
Vitiligo can occur in any type of cancer, according to a new study published as a preprint and that has not yet peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
COVID-19 Severity Does Not Differ for Patients With Skin Conditions
WEDNESDAY, Dec. 15, 2021 -- For patients with psoriasis, vitiligo, atopic dermatitis (AD), and chronic urticaria (CU), COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease, according to a letter to the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2021 Category: Pharmaceuticals Source Type: news
Can a Caucasian Have Vitiligo?
Title: Can a Caucasian Have Vitiligo?Category: Diseases and ConditionsCreated: 12/7/2021 12:00:00 AMLast Editorial Review: 12/7/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - December 7, 2021 Category: Dermatology Source Type: news
Connected skin therapy company Zerigo Health scores $43M
Zerigo Health, formerly Clarify Medical, makes a connected phototherapy device for skin conditions like psoriasis, vitiligo and eczema. (Source: mobihealthnews)
Source: mobihealthnews - October 21, 2021 Category: Information Technology Source Type: news
Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial
A topical formulation of the JAK inhibitor ruxolitinib produced statistically significant improvement in all primary and secondary outcomes relative to vehicle alone at 24 weeks.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 4, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
